Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:59 AM
Ignite Modification Date:
2025-12-25 @ 12:59 AM
NCT ID:
NCT06352593
Eligibility Criteria:
Inclusion Criteria:
* Aged \>18 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) I-III
* Unruptured subarachnoid hemorrhage (SAH) confirmed by digital subtraction catheter angiography (DSA) undergoing endovascular intervention with general anesthesia.
Exclusion Criteria:
* Subarachnoid hemorrhage (SAH) from a lesion other than a ruptured saccular aneurysm.
* Intraventricular or intracerebral blood in the absence of localized thick or diffuse Subarachnoid hemorrhage (SAH).
* No or localized thin subarachnoid hemorrhage (SAH) on computed tomography (CT).
* Cerebral vasospasm on admission digital subtraction catheter angiography (DSA).
* Hypotension (systolic blood pressure 90 mm Hg) refractory to fluid therapy.
* Neurogenic pulmonary edema.
* Cardiac failure requiring inotropic support.
* Severe or unstable concomitant condition or disease or chronic condition.
* Kidney and/or liver disease.
* Prior cerebral damage on computed tomography (CT) scan such as stroke (\>2 cm maximum diameter).
* Pregnancy.
* Traumatic brain injury.
* Previously treated cerebral aneurysm.
* Arterial venous malformation.
* Pre-existing cerebrovascular disorder that will affect diagnosis and evaluation of Subarachnoid hemorrhage (SAH).
* Ischemic heart disease or second or third-degree atrioventricular block.
* Long-term abuse of alcohol, opioids, or sedative-hypnotic drugs.
* Obesity (body mass index \[BMI\] \>30 kg/m2).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06352593
Study Brief:
Protocol Section:
NCT06352593